Sex, amyloid, and APOE epsilon 4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts

Grants

Funding Acknowledgements

R.F.B. is funded with the NHMRC Dementia Research Fellowship (APP1105576). J.R. is funded by the Canadian Institutes of Health Research Postdoctoral Fellowship. P.M. is a full-time employee of Cogstate Ltd. S.M.L. receives financial support from the CRC for Mental Health. The Cooperative Research Centre (CRC) program is an Australian Government Initiative. H.J. received funding from Alzheimer Nederland [WE.15-2014-06]. T.H. is funded by NIH (K01 040197). B.J.H. is funded by the Belgian American Education Foundation (BAEF); Belgian National Fund for Scientific Research (FNRS); and Saint-Luc Foundation. Y.Y.L. is funded with the NHMRC Dementia Research Fellowship (APP1111603). This work was supported with funding from the National Institutes of Health, including P01 AG036694 (Sperling and Johnson), P50 AG005134 (Sperling, Johnson, Hedden), K23 EB019023 (Sepulcre), K23 AG049087 (Chhatwal), K24 AG035007 (Sperling), and K01 040197 (Hedden). This research was carried out in part at the Athinoula A. Martinos Center for Biomedical Imaging at the Massachusetts General Hospital, using resources provided by the Center for Functional Neuroimaging Technologies, P41EB015896, a P41 Biotechnology Resource Grant supported by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health. This work also involved the use of instrumentation supported by the NIH Shared Instrumentation Grant Program and/or High-End Instrumentation Grant Program; specifically, grant numbers S10RR021110, S10RR023401, and S10RR023043. For ADNI, data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.